Diagnostic and Prognostic Value of miRNA 33 and miRNA122 in Metabolic Syndrome

Abstract

The metabolic syndrome (MetS) concept gathers in a single entity a set of metabolic abnormalities that have in common a close relationship with ectopic deposit of lipids, insulin resistance, and chronic low-grade inflammation. The aim of present study is to investigate whether patients with metabolic disorder have distinct expression of (miRNA122 and miRNA-33) when compared with different disease groups in addition to control group from the people whose apparent healthy. A case-control study was conducted on the study to identify the expression of (miRNA-122 and miRNA-33) by real time PCR, and the association of its susceptibility to Mets. There was a highly significant variation in the level of miR-33 among study groups (P< 0.001) particularly in group of central obesity, hypertension and diabetes group followed by central obesity and hypertensive group then by central obesity group and finally by control group. There was significant variation in level of miR-122 among study groups (p< 0.001). The highest level was seen in group of central obesity, hypertension and diabetes groups followed by central obesity and hypertensive group then by central obesity group and finally by control group In conclusion miR-33, along with miR-122 could be used to diagnose / prognostic biomarker with high sensitivity and specificity for metabolic disorders and cardiovascular disease.